Abstract 81P
Background
TRAIL-induced apoptosis pathway is a potential therapeutic target, but the majority of tumors are TRAIL-resistant. TRAIL receptors translocation is associated to TRAIL resistance. Besides TRAIL receptors, DR4 and DR5, other potentially TRAIL-induced apoptosis pathway regulatory proteins are: Apaf-1, CUL3, CLTA (clathrin chain A , involved in TRAIL receptors nuclear translocation) and KPNA-1 ( involved in TRAIL receptors internalization). Overcome TRAIL resistance is essential to therapeutic strategies development.
Methods
A549 cell line was used. Expression of miR-23b, miR-133a, DR4, DR5, Apaf-1, CUL3, CLTA/CLTC and KPNA-1 were estimated by RT-qPCR. Transfection effects of miR-23b inhibitor and Mimic-133a on TRAIL apoptosis pathway components expression. Western Blotting to TRAIL receptors compartmentalization after Mimic-133a and TRAIL stimulus. MTT cell viability assay to evaluate TRAIL-induced cytotoxicity of miR-23b inhibition and Mimic-133a transfection.
Results
A549 was TRAIL resistant. miR-23b was superexpressed and miR-23b inhibition upregulated Apaf-1 and CUL3 expression. miR-133a was undetectable. Mimic-133a transfection downregulated CLTA and DR5 expression. miR-23b inhibition and Mimic-133a transfection promoted TRAIL sensitization.TRAIL receptors were predominantly located in nuclear compartment. Mimic-133a downregulated CLTA expression but did not alter receptors compartmentalization. Mimic-133a and TRAIL associated stimulus leaded to predominant nuclear TRAIL receptors localization in comparison to control cells.
Conclusions
Both miR-23b and -133a are involved in TRAIL cells resistance. Apaf-1 and CUL3 expression downregulation by miR-23b can contribute to resistance. miR-133a role on TRAIL sensitization mechanisms must be further investigated. Mimic-133a downregulated CLTA expression but did not alter TRAIL receptors compartmentalization, suggesting that receptors translocation is clathrin independent.CLTA expression control by miR-133a, however, can contribute to drug-resistance research. Although more research is needed to fully clarify miRs roles on TRAIL-induced apoptosis, our findings deepen TRAIL resistance understanding.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09